Bispecific monoclonal antibody

AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Translation, Bispecific monoclonal antibody, Orange County Convention Center, AACR, Senior, ABCL, TCE, Antibody, Patient, Translational research, Trichloroethylene, Poster, Society, Vaccine, Dry cleaning, Partnering, AbCellera, PMHC cellular microarray

AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.

Key Points: 
  • AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being held at the Orange County Convention Center in Orlando, Florida, from April 14 to 19, 2023.
  • AbCellera debuted its TCE platform at AACR 2022 with data describing the diversity of its CD3-binding antibodies.
  • Presentations at AACR 2023 illustrated how AbCellera streamlines the development of TCEs with optimal functional properties for diverse tumor targets.
  • The presentation included:
    A comprehensive data package on a panel of CD3-binding antibodies, including binding and functional comparisons to molecules commonly used for TCE development.

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

Retrieved on: 
Monday, March 20, 2023
Bispecific monoclonal antibody, Pancreatic cancer, CD47, Macrophage, ADCC, ODD, Monoclonal antibody, RECIST, Pharmacokinetics, NK, Trial of the century, APC, Patient, ECOG, SAN, Cancer, ADCP, Neoplasm, Ageing, FDA, Therapy, Safety, Pharmaceutical industry

PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.

Key Points: 
  • PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.
  • The anti-CD47 arm of PT886 is highly differentiated and has demonstrated minimum binding to human red blood cells while maintains strong binding activity to CD47 on tumor cells.
  • "PT886 targets a validated tumor associated antigen in claudin 18.2 with enhanced anti-tumor activity and broadened tumor killing spectrum through a best-in-class anti-CD47 arm.
  • It is a product of Phanes' ingenious innovation in creative design of both novel therapeutic approaches and practical technologies," said Dr. Ming Wang, Founder and CEO of Phanes Therapeutics.

ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19

Retrieved on: 
Monday, March 13, 2023
IC50, SARS, Heel, Research, Infection, SARS-CoV-1, Bispecific monoclonal antibody, Life Sciences Institute, Coronavirus, SARS-CoV-2, Hook effect, COVID-19, Patient, BioRxiv, Immune system, Lipid, Structural biology, Antibody, Safety, VIB, Vaccine, XBB, Immunodeficiency, Epitope

Nearly all SARS-CoV-2 neutralizing antibodies that have been used in the clinic show substantial loss of potency against currently circulating variants.

Key Points: 
  • Nearly all SARS-CoV-2 neutralizing antibodies that have been used in the clinic show substantial loss of potency against currently circulating variants.
  • It targets a conserved region in the spike S2 subunit that is essential for viral entry.
  • It neutralizes all previous and current variants of concern and the currently most frequently circulating variants, including XBB, XBB.1.5, BQ.1.1 and BF.7.
  • The pharmacodynamic and safety properties of candidate drug molecules based on these S2-binding single domain antibodies were extensively evaluated in vitro and in vivo by ExeVir Bio.

InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China

Retrieved on: 
Friday, March 10, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ALL, NHL, Clinical trial, Hodgkin lymphoma, HKEX, Tafasitamab, Bispecific monoclonal antibody, Patient, Cancer, SSE, Hematology, Acute lymphoblastic leukemia, BTK, CD19, BCL2, Pharmaceutical industry, Vaccine

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in China.
  • ICP-248 is a novel, orally bioavailable BCL2 selective inhibitor, which aims to treat non- Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL) and other malignant hematological tumors as a monotherapy or in combination with BTK inhibitors and other drugs.
  • BCL2 is an important regulatory protein of apoptosis pathway, and its abnormal expression is related to the development of various hematologic malignancies.
  • ICP-248 has an anti-tumor effect by selectively inhibiting BCL2 and restoring the mechanism of programmed cell death.

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, ENPP3, Pembrolizumab, CD28, Caris, Cancer, RCC, Immune system, Cowen, Psoriasis, Laboratory, IND, CLDN6, Investment, Patient, Biology, R, Janssen, Neoplasm, CD20, Renal cell carcinoma, Bispecific monoclonal antibody, Therapeutic index, Sale, Antibody, CD3, Cytokine, Protein engineering, Novartis, Kidney cancer, Vir, G&A, Prostate, Atopic dermatitis, Vaccine, Cryptocurrency, Online shopping, Barclays, Regulatory T cell, Astellas Pharma, MorphoSys, Alexion

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022

Key Points: 
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022
    Cash, cash equivalents, receivables and marketable debt securities totaled $613.5 million as of December 31, 2022, compared to $664.1 million on December 31, 2021.
  • Total revenue for the fourth quarter ended December 31, 2022 was $21.6 million compared to $154.0 million for the same period in 2021.
  • General and administrative (G&A) expenses for the fourth quarter ended December 31, 2022 were $12.8 million compared to $11.4 million for the same period in 2021.
  • ET (1:30 p.m. PT) to discuss the full year 2022 financial results and provide a corporate update.

Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

Retrieved on: 
Wednesday, February 22, 2023
FDA, Pharmaceutical, Health, Oncology, Pfizer, Safety, PFE, Survival, RRMM, Breakthrough therapy, Priority review, NYSE, European Medicines Agency, Maintenance, Multiple myeloma, BLA, MM, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PRIME, MHRA, Attention, Probability, Cytokine release syndrome, Hematology, Inc., Innovative Medicines Canada, Bispecific monoclonal antibody, Medicines and Healthcare products Regulatory Agency, EMA, MAA, CRS, BCMA, Orphan, CD3, Food, Society, Vaccine, Pharmaceutical industry

The company is working closely with the EMA to facilitate their review and will provide updates on timing as appropriate.

Key Points: 
  • The company is working closely with the EMA to facilitate their review and will provide updates on timing as appropriate.
  • In November 2022, Pfizer announced that elranatamab was granted Breakthrough Therapy Designation by the FDA.
  • In addition, elranatamab has been granted Orphan Drug Designation by the FDA and the EMA for the treatment of MM.
  • The FDA and EMA have also granted elranatamab Fast Track Designation and the PRIME scheme, respectively, for the treatment of patients with RRMM.

Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets

Retrieved on: 
Tuesday, February 21, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, G protein-coupled receptor, HKEX, Antigen, Project, Spacecraft, RAC, Epitope, DSM-IV codes, CDR3, Neoplasm, Bispecific monoclonal antibody, ADC, Hook effect, Antibody, Medication, Cytokine, Service provider, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.
  • The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
  • Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”.
  • The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases.

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

Retrieved on: 
Monday, February 13, 2023
Molecule, Trae tha Truth, Fever, Toxicity, Fatigue, Docetaxel, PSA, Therapy, Rash, PD-1, Aes, TILS, Bispecific monoclonal antibody, Prostate, Metastasis, Macrogen, RECIST, Melanoma, Hypothyroidism, Cell, AE, Tumor microenvironment, Poster, Risk, Death, Lung cancer, Itch, Society, Cancer, Resuscitation, Pharmaceutical industry, PD, Patient

Confirmed objective responses were observed across the histology-specific cohorts; preliminary efficacy results for mCRPC are presented in the poster and below.

Key Points: 
  • Confirmed objective responses were observed across the histology-specific cohorts; preliminary efficacy results for mCRPC are presented in the poster and below.
  • Median exposure was 14.4 weeks (range: 1.9 - 100.1 weeks) with a median of four infusions administered per patient.
  • A total of 35 patients with mCRPC had measurable soft tissue disease per RECIST v1.1 at study entry.
  • We believe we are seeing the benefit of lorigerlimab’s design and are very encouraged by this latest data set from our ongoing Phase 1 study.

Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets

Retrieved on: 
Tuesday, February 21, 2023
Biotechnology, Infectious Diseases, Health, Stem Cells, Pharmaceutical, ADC, Service provider, RAC, Medication, Project, G protein-coupled receptor, Hook effect, Epitope, Research, Neoplasm, DSM-IV codes, Cytokine, Antibody, Antigen, Bispecific monoclonal antibody, Spacecraft, HKEX, CDR3, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets.
  • The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNanoTM, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
  • Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”.
  • The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases.

Adimab Provides 2022 Update on Clinical Pipeline

Retrieved on: 
Wednesday, January 11, 2023
Health, Stem Cells, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Partner, G protein-coupled receptor, Control, Ion, Complex, Monoclonal antibody, Cytokine, Bispecific monoclonal antibody, HC, TCR International Series, ADC, Engineering, CAR, BLA, Therapy, FC, CD3, Antibody, Melinda Gates, Nextpoint, Bill & Melinda Gates Foundation, Immunoglobulin G, Top of the Form (quiz show), Bristol Myers Squibb, Sintilimab, Vaccine, Biotechnology Innovation Organization

This brings the total number of Adimab partner programs that have entered the clinic to 62.

Key Points: 
  • This brings the total number of Adimab partner programs that have entered the clinic to 62.
  • Partners have recently filed for BLA approval on three additional programs and another three programs are currently in pivotal trials.
  • “Over the last five years alone, partners have initiated clinical trials for 52 new programs.
  • Bispecifics and T-cell engagers: Adimab has extensive bispecific and multispecific capabilities, including common light chain and fragment-based discovery and engineering.